The VEGF-A inhibitor sFLT-1 improves renal function by reducing endothelial activation and inflammation in a mouse model of type 1 diabetes
Crossref DOI link: https://doi.org/10.1007/s00125-017-4322-3
Published Online: 2017-06-15
Published Print: 2017-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Bus, Pascal
Scharpfenecker, Marion
Van Der Wilk, Priscilla
Wolterbeek, Ron
Bruijn, Jan A.
Baelde, Hans J.
Funding for this research was provided by:
Leiden University Medical Center (LUMC)
License valid from 2017-06-15